ArticleNpj mental health research2025
Real-world effectiveness of a widely available digital health program in adults reporting a lifetime diagnosis of ADHD.
Article in Npj mental health research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Digital health technologies for adults with ADHD: a scoping review.Frontiers in digital health · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We examined real-world evidence on whether Lumosity, a remote digital health technology designed to deliver cognitive training to healthy adults, can improve cognition and reduce inattention in adults who reported having received a prior (lifetime) diagnosis of ADHD. Over the course of Lumosity training, this cohort of commercial users was assessed repeatedly online with a neuropsychological test battery (NCPT) and a scale of attention and mood in real-world contexts (BAMS-7). More Lumosity training between successive assessments led to greater improvements on the NCPT composite measure and the attentional subscale of the BAMS-7. This positive dose-response relation was found for six of eight NCPT subtests and three of four BAMS-7 attentional items. Additional findings support the participants' clinical status and sensitivity of the assessments to ADHD symptoms. These findings provide evidence of cognitive and attentional benefits in a real-world cohort of adults reporting a lifetime diagnosis of ADHD from training with Lumosity under real-world conditions.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.